INTEGRIS-IPF: A Phase 2a Clinical Trial of PLN-74809 in Patients with IPF JULY 11, 2022 © 2022 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances ...

Developing Novel Treatments for Fibrotic Diseases 41st Annual J.P. Morgan Healthcare Conference JANUARY 10, 2023 © 2023 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not ...

AeroVironment, Inc. Fourth Quarter Fiscal 2016 Overview Presentation July 5, 2016 © 2016 AeroVironment, Inc. Safe Harbor Statement 2 | July 19, 2016 © 2016 AeroVironment, Inc. Certain statements in this document may constitute "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are made on the basis of current expectations, forecasts and assumptions that involve risks and uncertainties, including, but not limited to, economic, compet ...

AeroVironment Fourth Quarter Fiscal 2019 Investor Overview June 27, 2019 1 June 27, 2019 June 27, 2019 August 2, 2017 © 2019 AeroVironment, Inc. © 20179 AeroVironment, Inc. AeroVironment, Inc. Safe Harbor Statement 2 June 27, 2019 © 2019 AeroVironment, Inc. Certain statements in this presentation may constitute "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, f ...

业绩总结 - 第四季度收入为1.35亿美元，全年收入为3.67亿美元，同比增长17%[5] - 全年毛利润为1.53亿美元，同比增长19%[7] - 每股收益（摊薄后）为1.72美元，非GAAP每股收益为1.84美元[7] - 资金积压为2.08亿美元，同比增长27%[7] 用户数据 - 小型无人机（UAS）收入为2.26亿美元，主要受国内需求强劲推动[12] - HAPS项目合同价值增长至1.66亿美元[12] 未来展望 - 2021财年收入预期在3.90亿美元至4.10亿美元之间[16] - 2021财年运营利润率预期为12%至12.5%[16] - 2021财年税率预期约为12%[16] 研发投资 - 2020财年内部研发投资占收入的13%[16]

LEADING THE DEFENSE TECH SECTOR TECHNOLOGY // CAPACITY // EXPERIENCE NASDAQ // NEW YORK CITY 27 JUNE 2024 1 1 | © 2024 AeroVironment, Inc. – Proprietary Information Safe Harbor Statement Certain words in this presentation may contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

William Blair Growth Stock Conference NASDAQ: AVAV June 3, 2025 DEFINING THE NEXT ERA OF DEFENSE TECHNOLOGY Slide 1 © 2025 AeroVironment, Inc. Safe Harbor Statement This presentation contains statements regarding AeroVironment, Inc. ("AV"), including its wholly owned subsidiary BlueHalo, that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") ...

Delivering on the promise of Prime Editing This presentation contains forward-looking statements of Prime Medicine, Inc. ("Prime", "we" or "our") within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements contain information about our current and future prospects and our operations, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements rega ...

Key Takeaways IBKR's June DARTs rose 39.7% YoY to 3.45M, boosting shares by 3.4% on increased client activity. The company's global expansion and tech upgrades continue to support strong revenue momentum. Non-interest expenses climbed at a 13.8% CAGR through 2024 and remained elevated in early 2025.Interactive Brokers Group, Inc. (IBKR) reported a rise in its client Daily Average Revenue Trades (DARTs) on a year-over-year basis for June 2025. In light of this, shares of the company rose 3.4% in yesterday’ ...